Isoform-specific anti-MeCP2 antibodies confirm that expression of the e1 isoform strongly predominates in the brain

F1000Res. 2013 Oct 4:2:204. doi: 10.12688/f1000research.2-204.v1. eCollection 2013.

Abstract

Rett syndrome is a neurological disorder caused by mutations in the MECP2 gene. MeCP2 transcripts are alternatively spliced to generate two protein isoforms (MeCP2_e1 and MeCP2_e2) that differ at their N-termini. Whilst mRNAs for both forms are expressed ubiquitously, the one for MeCP2_e1 is more abundant than for MeCP2_e2 in the central nervous system. In transfected cells, both protein isoforms are nuclear and colocalize with densely methylated heterochromatic foci. With a view to understanding the physiological contribution of each isoform, and their respective roles in the pathogenesis of Rett syndrome, we set out to generate isoform-specific anti-MeCP2 antibodies. To this end, we immunized rabbits against the peptides corresponding to the short amino-terminal portions that are different between the two isoforms. The polyclonal antibodies thus obtained specifically detected their respective isoforms of MeCP2 in Neuro2a (N2A) cells transfected to express either form. Both antisera showed comparable sensitivities when used for Western blot or immunofluorescence, and were highly specific for their respective isoform. When those antibodies were used on mouse tissues, specific signals were easily detected for Mecp2_e1, whilst Mecp2_e2 was very difficult to detect by Western blot, and even more so by immunofluorescence. Our results thus suggest that brain cells express low amounts of the Mecp2-e2 isoform. Our findings are compatible with recent reports showing that MeCP2_e2 is dispensable for healthy brain function, and that it may be involved in the regulation of neuronal apoptosis and embryonic development.

Grants and funding

This work was supported by Association Française du Syndrome de Rett (AFSR), the Fondation pour la Recherche Medicale (FRM) and the E-RARE EuroRETT network. JCR and EJ were supported by INSERM (Institut National pour la Santé et la Recherche Médicale). NP was supported by an INSERM-Région Provence-Alpes-Côte d’Azur fellowship, HM was supported by CNRS (Centre National pour la Recherche Scientifique).